Efficacy of a food supplement Lertal® as an adjuvant therapy of patients with moderate-to-severe seasonal allergic rhinoconjunctivitis

The Egyptian Journal of Otolaryngology

Table 4 Statistical significances of differences in the percents of improvement in nasal and ocular symptoms (V2 vs V1–V1 vs V0)

Procedure: 1=A–A+L; 2=A+C–A+C+L; 3=A–A; 4=A+C–A+C		Sneezing V2 vs V1–V1 vs V0	Tearing V2 vs V1–V1 vs V0	Ocular itching V2 vs V1–V1 vs V0	Rhinorrhea V2 vs V1–V1 vs V0	Nasal obstruction V2 vs V1–V1 vs V0	Hyposmia V2 vs V1–V1 vs V0	Cough V2 vs V1–V1 vs V0
1	Z	−4.029^b	−4.033^b	−4.050^b	−4.028^b	−2.356^b	−.801^b	−2.881^b
1	Sig. (2-tailed)	.000	.000	.000	.000	.018	.423	.004
2	Z	−3.854^b	−3.837^b	−3.859^b	−3.847^b	−3.570^b	−2.868^b	−2.785^b
2	Sig. (2-tailed)	.000	.000	.000	.000	.000	.004	.005
3	Z	−2.643^b	−1.353^b	−.283^b	−1.225^b	−2.247^c	−2.963^c	−3.295^c
3	Sig. (2-tailed)	.008	.176	.777	.221	.025	.003	.001
4	Z	−3.251^b	−2.613^b	−2.677^b	−3.016^b	−2.220^c	−1.002^c	−2.457^c
4	Sig. (2-tailed)	.001	.009	.007	.003	.026	.316	.014

Abbreviations: V0 before treatment (day 0), V1 visit 1 (day 30), V2 visit 2 (day 60)
^aWilcoxon signed rank test
^bBased on positive ranks
^cBased on negative ranks